Olopatadine Eye Drops and Allergy Skin Testing

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University Medical Center
• Treatments: Olopatadine Hydrochloride; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Adults aged 18 to 75 years

• Healthy volunteers (no major illnesses or active symptoms)

Exclusion Criteria:

• Known allergy or hypersensitivity to the drugs or components

• Pregnant or nursing women

• Women wishing to become pregnant during the study's duration

• Use of topical or oral medications with antihistaminic activity for 14 days proceeding randomization

• Dermatographism as evidenced on skin testing on visit 1

• Chronic urticaria active within the past 6 months

• Severe hypertension

• Psychiatric diagnoses which could potentially affect medication compliance, such as schizophrenia or delusional disorders, as determined by the investigator obtaining informed consent and based on the subject's past medical history

• Inability to provide informed consent